EMA Authorised: Arexvy — GlaxoSmithKline Biologicals S.A.

View source ↗

Summary

The EMA has authorised Arexvy by GlaxoSmithKline Biologicals S.A. for respiratory syncytial virus infections. Decision date: 19 February 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• Arexvy

Snippet

Status: Authorised. Therapeutic area: Respiratory Syncytial Virus Infections. MAH: GlaxoSmithKline Biologicals S.A.. Decision date: 19/02/2026